NCT06257043View on ClinicalTrials.gov

"Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in Real World Chinese Patients"

RecruitingOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

November 1, 2033

Study Completion Date

January 1, 2034

Conditions
Aortic Valve Disease Mixed
Interventions
PROCEDURE

Transcatheter aortic valve replacement

A total of 3000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled at 30-50 centers. The devices used will be all post-market transcatheter aortic valves approved for use in China. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years

Trial Locations (1)

710032

RECRUITING

Ling Tao, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER